New partnership with ProQR Therapeutics, a pioneer in next-generation RNA technology, for the further development of 2 projects: sepofarsen and ultevursen.
This acquisition represents a new step for Théa in the research and treatment of rare genetic eye diseases.
"These two promising products offer new prospects for patients", says Jean-Frédéric Chibret.
A dedicated team of experts specializing in hereditary retinal diseases (IRD) will be set up to manage these two innovative projects.
This strategic collaboration between Théa and ProQR Therapeutics opens up exciting new prospects in the field of eye care.
Read the Press Release here